Tag Archive for: POLB 001

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

/in

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]

Read more

Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial

/in

Strong potential for POLB 001 to be a blockbuster treatment for severe influenza Key Highlights ·      POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines ·      POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo ·    Trial results demonstrate expected utility in severe influenza […]

Read more

Poolbeg announces strategic expansion of POLB 001 into oncology

/in

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights ·      Newly filed patent application to protect use of POLB 001 for new oncology indication ·      Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]

Read more

Positive Initial Data Analysis in POLB 001 LPS Challenge Trial

/in

Early data read out indicates a successful LPS human challenge trial Key Highlights ·      POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo ·      A clear dose-response relationship was demonstrated                                                                 ·      Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported ·      Full […]

Read more

Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023

/in

12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the […]

Read more